nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Readiness
Report #NBU-26510944·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.3 Neurology and psychiatry·Subfield: Public Health, Environmental and Occupational Health·Basis: Full text·Type: Laboratory experiment

Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease.

Avilés-Granados et al.Avilés-Granados, Gea-González, Sáez-Leyva et al.·2026·Acta neuropathologica communications·10.1186/s40478-026-02289-9 ↗

Primary claim

increased levels of the active TMPRSS2 protease constitute a potential risk factor for enhanced entrance of SARS-CoV-2 into the brain of individuals with DS

Tentative · cross-sectional protein abundance does not identify catalytic activity, viral entry, or infection susceptibility
In brief

Species-resolved profiling identifies distinct DS and AD protein patterns, but small unmatched cohorts prevent firm conclusions about viral susceptibility.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Individuals with Down syndrome (DS) and Alzheimer’s disease (AD) are vulnerable to COVID-19, but whether alterations in ACE2, the viral receptor, and TMPRSS2, the spike-priming protease for SARS-CoV-2, differ between these disorders is unknown. We analyzed cleaved fragments and full-length species of ACE2 and TMPRSS2 in the cerebrospinal fluid (CSF) from non-infected individuals with DS (n = 9) without memory decline (nDS), DS with dementia (dDS; n = 10) and aged matched controls (n = 10). CSF levels were compared to levels in frozen postmortem frontal cortex in nDS (n = 4), dDS (n = 8) and 11 controls using quantitative fluorescent western blotting. We also examined CSF (19 AD and 19 age-matched non-AD controls) and frontal cortex from 30 AD cases and 7 non-disease controls. CSF and frontal cortex TMPRSS2 full-length zymogen and active protease-domain fragment were significantly increased in nDS, but not in dDS despite elevated zymogen. In contrast, AD CSF and frontal cortex levels of the TMPRSS2 protease fragment and zymogen remained unchanged. Regarding the viral receptor, an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS. In frontal cortex, full-length ACE2 levels were preserved in nDS compared to controls, but several ACE2 species (120 and 110 kDa full-length, and 80 kDa fragment) were significantly decreased in dDS compared to nDS and controls. In contrast, CSF ACE2 130 kDa full-length levels were decreased compared to an increase in the fragment/full-length ratio in AD compared to controls, opposite to DS. In AD, frontal cortex levels of the 150 kDa ACE2 full-length species was significantly reduced across all Braak stages. ACE2 immunohistochemistry and immunofluorescence of frontal cortex sections revealed positive puncta in the neuropil, astrocytes and blood vessels in AD and DS with or without dementia. Overall, we found an increase in active TMPRSS2 and reduced soluble ACE2 fragments individuals with DS, particularly those without dementia, which differs from that observed in AD that may differentially affect susceptibility to COVID-19 viral infection in these conditions.

Key Claims

Primary finding · Tentative

increased levels of the active TMPRSS2 protease constitute a potential risk factor for enhanced entrance of SARS-CoV-2 into the brain of individuals with DS

Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

cross-sectional protein abundance does not identify catalytic activity, viral entry, or infection susceptibility

Discussion, paragraph beginning “Taken together, the results indicate”
Quote verified
Secondary · Supported

CSF and frontal cortex TMPRSS2 full-length zymogen and active protease-domain fragment were significantly increased in nDS, but not in dDS

concordant CSF and cortex differences, constrained by four nDS cortex cases and age imbalance

Abstract; Results, Figs. 1 and 3
Quote verified
Secondary · Tentative

an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS

the dDS quotient interpretation conflicts with the Results wording despite a reported P=0.046

Abstract; Results, Fig. 5B–C
Quote verified
Secondary · Supported

In AD, frontal cortex levels of the 150 kDa ACE2 full-length species was significantly reduced across all Braak stages

stage-consistent reported differences, tempered by a seven-case control group and multiple outlier exclusions

Abstract; Results, Fig. 8A–B
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Species-resolved cross-disorder molecular comparison

ACE2 and TMPRSS2 full-length forms and fragments are compared across nDS, dDS, AD, and controls in both CSF and frontal cortex, delineating patterns that total-protein measurements could obscure.

↳ Abstract; Results, Figs. 1–8

#methodological rigour

Documented biochemical measurement controls

The study reports serial-dilution checks for linear detection, duplicate independent blots, a shared CSF inter-blot normalizer, and vinculin normalization for brain extracts.

↳ Methods, quantitative fluorescent western blotting

#positioning

Conflicting ACE2 literature addressed

The Discussion presents prior reports of increased, unchanged, and reduced ACE2-related measures in AD and identifies methodological and regional explanations for disagreement.

↳ Discussion, paragraph beginning “Previous transcriptomic and proteomic studies”

Limitations

#methodological rigour

Small, unmatched cortex comparison groups

The nDS cortex group contains four cases and is approximately 20 years younger than controls, while dDS cases also differ in age. No covariate-adjusted confounding strategy is reported.

↳ Methods, DS case demographics; Discussion, limitations paragraph

#reporting

Internal ACE2 reporting contradiction

The dDS ACE2 quotient is described as a reduction that “was not seen” despite P=0.046, whereas the abstract and Fig. 5 title report a reduction in both DS groups.

↳ Abstract; Results, CSF ACE2 analysis; Fig. 5C

#reporting

Susceptibility claims exceed measured outcomes

The study measures protein abundance but not catalytic activity, blood-brain barrier integrity, viral entry, infection, or clinical susceptibility. Separate cohorts also preclude a direct DS-versus-AD specificity test.

↳ Discussion, TMPRSS2 interpretation, ACE2 immunoreactivity, and summary paragraphs

Does this match your read? Add your assessment ↓

Nabu Commentary

Species-specific measurements across CSF and frontal cortex provide a useful descriptive comparison of DS subtypes and sporadic AD. The western-blot workflow includes linear-range, normalization, and duplicate-blot controls, but the cortex evidence is constrained by four nDS cases, marked age imbalance, extensive testing, and outlier exclusions. The Discussion moves beyond measured abundance to catalytic activity, blood-brain barrier disruption, viral entry, and DS-specific susceptibility without functional assays or direct cross-cohort tests. The findings therefore support hypothesis generation rather than clinical or mechanistic conclusions.

Check another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Study Quality

Sound3.0

Confidence medium
Contribution
3.3

The study adds a species-resolved comparison of ACE2 and TMPRSS2 across CSF and frontal cortex in DS subtypes and AD. The advance is identifiable but primarily descriptive and constrained by small, unreplicated groups.

Abstract; Results, Figs. 1–8

CSF and frontal cortex TMPRSS2 full-length zymogen and active protease-domain fragment were significantly increased in nDS

Methodological Rigour
2.7

Fluorescent detection, duplicate independent blots, inter-blot normalization, and vinculin controls support the biochemical measurements. Confidence is reduced by the nDS cortex sample of four, age imbalance, uncorrected multiplicity, ROUT exclusions, qualitative IHC, and unreported blinding or randomization.

Methods, DS case demographics, fluorescent western blotting, IHC, and statistical analysis; Figs. 3, 8, and 9

All samples were analyzed at least in duplicate on independent blots.

Reporting
3.2

The CSF and cortex findings are organized by protein species and diagnostic group, making the main comparisons traceable. Central discussion claims about catalytic activity, viral entry, and DS specificity exceed the measured abundance data, and the P=0.046 wording creates a direct local contradiction.

Results, Fig. 5C; Discussion, summary paragraphs

triplication in DS leads to an increase in TMPRSS2 protein levels, potentially resulting in an increase in its catalytic activity

Positioning
3.3

The Discussion addresses conflicting reports of increased, unchanged, and reduced ACE2 measures in AD and explicitly lists major cohort limitations. Those limitations are not fully integrated into the closing claims of DS-specific susceptibility and therapeutic relevance.

Discussion, prior ACE2 literature, limitations paragraph, and concluding paragraphs

the present finding should be considered conservatively and replicated using a larger cohort of cases

Reliability

Caveats4 of 4 checks


Results checkNoted
  • an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS: "This quotient confirmed a significant reduction of the cleaved fragment in relation to the unprocessed form in nDS (P = 0.008), which was not seen in dDS (P = 0.046) compared to disomic controls (Fig. 5C)." (Results, CSF ACE2 analysis in DS and AD) vs "P values < 0.05 were considered significant." (Methods, Statistical analysis). The reported dDS quotient P = 0.046 is below the stated 0.05 threshold, contradicting the sentence's denial of a significant reduction. → Not supported by the paper's own data
Reporting and transparencyNoted

The TMPRSS2 cortex legend reports 10 controls versus 11 in the cohort description without explaining the difference, and the study explicitly discloses that it was not preregistered; neither establishes a changed numerical result.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared

Reference IntegrityClean

63 references in manuscript 63 of 63 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Readiness

Where this paper’s evidence sits on the path from initial observation to real-world use.

Mechanistic

The findings are cross-sectional protein-abundance observations in CSF and postmortem tissue. No viral-entry, catalytic-activity, treatment-response, or clinical-outcome experiment establishes a near-term application.

Methods, fluorescent western blotting; Discussion, therapeutic implications
Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society

    Di Domenico, Perluigi, Tramutola, et al. · 2026 · Clinical medicine

    Primary claim

    DS research has entered a new era characterized by precision, translation, and global cooperation.

    Tentative
    Study quality
    Limited2.9
    Reliability
    Caveats
  2. Plant-Based Dietary Patterns and Incidence of Type 2 Diabetes in US Men and Women: Results from Three Prospective Cohort Studies

    Satija, Bhupathiraju, Rimm, et al. · 2016 · Clinical medicine

    Primary claim

    Our study suggests that plant-based diets, especially when rich in high-quality plant foods, are associated with substantially lower risk of developing T2D.

    Supported
    Study quality
    Strong3.8
    Reliability
    No concerns
  3. Randomised crossover controlled trial of dietary interventions for glycaemic control when body weight is kept stable

    Fontes-Villalba, Fika-Hernando, Picazo, et al. · 2025 · Clinical medicine

    Primary claim

    Characteristic food group differences and the accompanying differences in fibre content between a Palaeolithic and a diabetes diet do not cause an effect on glycaemic control.

    Tentative
    Study quality
    Sound3.2
    Reliability
    Caveats

How the rubric works →